文献速递肺结节与肺癌

转移性非小细胞肺癌伴EGFR或ALK突变患者症状性恶性胸腔积液复发的危险因素与复发时间

Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
PubMed 文献 · Chest · 2020-11-17

本研究为回顾性队列研究,纳入396例因恶性胸腔积液首次行胸腔穿刺的转移性非小细胞肺癌患者,其中101例(25.5%)存在可靶向治疗的突变。分析显示,可靶向突变患者与无突变患者的恶性胸腔积液复发风险在多变量分析中无显著差异,而胸片显示积液量较大、胸水乳酸脱氢酶较高及细胞学检查阳性与复发风险增加相关。

要点

  • 可靶向突变患者与无突变患者的恶性胸腔积液复发风险相似。
  • 胸片积液量较大、胸水LDH较高及细胞学阳性增加复发风险。
  • 可靶向突变患者可能受益于类似的 definitive 胸腔积液管理策略。

核心结论

  • 可靶向突变患者与无突变患者的恶性胸腔积液复发风险相似,可能受益于类似的 definitive 管理策略。

研究设计与样本

  • 回顾性队列研究,纳入396例因恶性胸腔积液首次行胸腔穿刺的转移性非小细胞肺癌患者,其中295例(74.5%)无突变,101例(25.5%)有可靶向突变。

主要发现

  • 可靶向突变患者中90%在首次胸腔穿刺后30天内接受靶向治疗。
  • 单因素分析显示可靶向突变患者恶性胸腔积液复发风险显著更高,但多因素分析中差异不显著。
  • 胸片显示积液量较大(P < .001)、胸水乳酸脱氢酶较高(P < .001)及细胞学检查阳性(P = .008)与复发风险增加相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The main goal of management in patients with non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE) is palliation. Patients with MPE and actionable mutations, because their disease is expected to respond quickly and markedly to targeted therapy, are less likely than those without actionable mutations to receive definitive MPE management. Whether such management is indicated in these patients is unclear. RESEARCH QUESTIONS: What is the time to ipsilateral MPE recurrence requiring intervention in patients with metastatic NSCLC by mutation status? What are the risk factors for MPE recurrence? STUDY DESIGN AND METHODS: Retrospective cohort study of consecutive patients who underwent initial thoracentesis for MPE. We used a Fine-Gray subdistribution hazard model to calculate the time to ipsilateral MPE recurrence requiring intervention within 100 days of initial thoracentesis and to identify variables associated with time to pleural fluid recurrence. RESULTS: A total of 396 patients, comprising 295 (74.5%) without and 101 (25.5%) with actionable mutations, were included. Most patients with actionable mutations (90%) were receiving targeted treatment within 30 days of initial thoracentesis. On univariate analysis, patients with actionable mutations showed a significantly higher hazard of MPE recurrence. On multivariate analysis, this difference was not significant. Larger pleural effusion size on chest radiography (P < .001), higher pleural fluid lactate dehydrogenase (P < .001), and positive cytologic examination results (P = .008) were associated with an increased hazard of recurrence. INTERPRETATION: Our findings indicate that patients with actionable mutations have a similar risk of MPE recurrence when compared with patients without mutations and would benefit from a similar definitive management approach to MPE.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Schwalk AJ, Ost DE, Saltijeral SN, et al. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest. 2020. PMID: 33217413. doi:10.1016/j.chest.2020.10.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。